Could vimseltinib be the next big thing in TGCT treatment? FDA says Yes!
The U.S. Food and Drug Administration (FDA) has granted priority review status to Deciphera Pharmaceuticals, Inc.'s New Drug Application (NDA) for vimseltinib, a drug developed ... Read More
ONO Pharmaceutical to acquire Deciphera Pharmaceuticals in $2.4bn deal
ONO Pharmaceutical, Co., Ltd., has entered into a definitive agreement to acquire all outstanding shares of Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), for $25.60 per share ... Read More
Deciphera gets Qinlock FDA approval for fourth-line advanced GIST
Qinlock FDA approval : Deciphera Pharmaceuticals has been granted approval from the US Food and Drug Administration (FDA) for Qinlock (ripretinib) in advanced gastrointestinal stromal ... Read More